FDA 483 - ABC Pharmaceuticals

Revance Therapeutics, Inc. in Newark, CA, a drug substance and drug product manufacturer, was inspected by the FDA. The inspection revealed significant deficiencies in cell bank testing, manufacturing process control, quality unit oversight of outsourced activities, yield determination, and written procedures for quality control. These issues indicate a lack of robust quality systems and process control, potentially impacting product quality and regulatory compliance.